Table 5.
Drug Preference Shares for Market Simulation Base-Case and Alternative Scenarios
| Medicare beneficiaries | Commercially insured patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| JAK1 | TNF inhibitor | PDE inhibitor | TNF inhibitor | IL-17 | JAK1 | TNF inhibitor | PDE inhibitor | TNF inhibitor | IL-17 | |
| Drug concept | Tofacitinib | Adalimumab | Apremilast | Infliximab | Secukinumab | Tofacitinib | Adalimumab | Apremilast | Infliximab | Secukinumab |
| Base case,a,b % | 29.0 | 50.6 | 2.8 | 6.4 | 11.2 | 17.4 | 25.4 | 10.8 | 7.1 | 39.4 |
| Alternative scenario,b,c % | 17.2 | 27.6 | 17.2 | 10.4 | 27.6 | 17.8 | 27.5 | 17.8 | 9.4 | 27.5 |
a
The base case assumes all drug attributes displayed in the top panel of Table 4.
b
Each row should sum to 100% (± rounding error).
c
The alternative case assumes all efficacy and safety attributes to be the same between drug concepts, with differences only in the route and frequency of administration.
IL indicates interleukin; JAK, Janus kinase; PDE, phosphodiesterase; TNF, tumor necrosis factor.